Oak Thistle LLC Raises Holdings in Henry Schein, Inc. $HSIC

Oak Thistle LLC grew its holdings in Henry Schein, Inc. (NASDAQ:HSIC) by 157.1% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,052 shares of the company’s stock after purchasing an additional 9,197 shares during the period. Oak Thistle LLC’s holdings in Henry Schein were worth $1,257,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. CYBER HORNET ETFs LLC purchased a new stake in shares of Henry Schein during the second quarter valued at $25,000. MUFG Securities EMEA plc purchased a new position in Henry Schein in the 2nd quarter worth about $27,000. Flagship Harbor Advisors LLC purchased a new position in Henry Schein in the 4th quarter worth about $30,000. Federated Hermes Inc. bought a new position in Henry Schein during the 4th quarter valued at about $32,000. Finally, Los Angeles Capital Management LLC bought a new position in Henry Schein during the 4th quarter valued at about $37,000. 96.62% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the stock. Barrington Research set a $104.00 price target on shares of Henry Schein in a research note on Wednesday, August 5th. BMO Capital Markets began coverage on shares of Henry Schein in a research report on Wednesday, July 8th. They set a “market perform” rating and a $85.00 price objective on the stock. Morgan Stanley restated an “underweight” rating and issued a $64.00 target price (up from $61.00) on shares of Henry Schein in a report on Friday, April 24th. Citigroup reaffirmed a “buy” rating and issued a $112.00 target price (up from $100.00) on shares of Henry Schein in a research report on Wednesday, August 5th. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of Henry Schein in a research note on Friday, July 31st. Eight equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $92.27.

Henry Schein Trading Up 1.7%

Shares of NASDAQ:HSIC opened at $90.74 on Thursday. The stock’s 50-day simple moving average is $84.28 and its two-hundred day simple moving average is $78.89. The stock has a market capitalization of $10.11 billion, a price-to-earnings ratio of 26.45, a PEG ratio of 1.70 and a beta of 0.80. Henry Schein, Inc. has a 52-week low of $61.94 and a 52-week high of $92.18. The company has a debt-to-equity ratio of 0.60, a quick ratio of 0.73 and a current ratio of 1.32.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $1.27 earnings per share for the quarter, topping the consensus estimate of $1.24 by $0.03. The firm had revenue of $3.46 billion for the quarter, compared to analysts’ expectations of $3.37 billion. Henry Schein had a net margin of 2.96% and a return on equity of 15.97%. The business’s quarterly revenue was up 6.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.10 EPS. Henry Schein has set its FY 2026 guidance at 5.290-5.390 EPS. Analysts expect that Henry Schein, Inc. will post 5.35 EPS for the current year.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.